PRECISION RESEARCH
AND DEVELOPMENT
ACCELERATES
ACCESS TO CARE
Bringing novel therapies to market is
costly and time consuming.
$1B
Average R&D costs
for novel therapeutics
52%
Respiratory drugs that fail
at phase III and beyond
Bringing novel therapies
to market is
costly and time consuming.
$1B
Average R&D costs for novel therapeutics
52%
Respiratory drugs that fail at phase III and beyond
AI-based solutions improve patient selection and help predict drug efficacy.
VIDA Discovery modernizes the clinical trial process
VIDA provides quality, quantitative CT imaging analysis for all major lung and respiratory diseases to streamline clinical trials with leading protocols.
- 50+ Lung Imaging Biomarkers Dictionary
- 500+ participating sites
- Large Curated Data Repository
- Patented Algorithms
- Phantom Access/Calibration Program
- FDA, CE, TGA and CMDCAS certified
- ISO-13485 compliant core lab process
ENHANCE PATIENT SELECTION
AI generated imaging biomarkers & advanced analytics ensure the strongest candidate selection criteria
BOOST
STUDY POWER
STUDY POWER
Advanced imaging endpoints often enables fewer clinical subjects for statistical significance while increasing sensitivity
IMPROVE CLINICAL EFFICACY
Lung imaging biomarkers can reveal a clear understanding of treatment effects and enable faster decisions
8
Languages
supported
30
Countries
engaged
13
Years of clinical trial
experience
20
Academic
partners
200
Peer-reviewed
publications
8
Languages supported
30
Countries engaged
13
Years of clinical trial experience
20
Academic partners
200
Peer-reviewed publications
60+ successful academic and industry clinical trials
60+ successful academic and industry clinical trials
What lung care professionals say about VIDA
“I’ve enjoyed working with VIDA for several years now and hope to do so also in future trials. They are, in my opinion, the provider with the best understanding (by far) of the challenges involved in using CT imaging in COPD/asthma clinical trials.”
“I’ve worked with VIDA for over 10 years. They are the scientific leader in the field. I’ve found their imaging analysis to be invaluable for evaluating lung phenotypes, including assessing response to biologic therapy in asthma patients.”
